Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in the ...

Vaccines are a clinical product that is composed of live or dead material from an infectious agent – bacterium, virus, fungus or parasite – that elicit protective immunity against the pathogen ...

The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has quite a bit of cash and some promising candidates. The main reason ...

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial ...

The AstraZeneca and Johnson & Johnson vaccines were linked to a rare, but serious, blood clot in the brain and their use was restricted to certain groups. The Pfizer and Moderna jabs, meanwhile ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Babies are supposed to receive vaccines that protect against about 15 different infectious diseases. Most require more than one dose, which amounts to nearly 30 jabs by age two. Parents may be ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...